Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
MODERNA INC (1MRNA.MI) Stock Price & Overview
BIT:1MRNA • US60770K1079
Current stock price
40.275 EUR
-5.02 (-11.09%)
Last:
The current stock price of 1MRNA.MI is 40.275 EUR. Today 1MRNA.MI is down by -11.09%. In the past month the price increased by 23.59%. In the past year, price increased by 46.33%.
1MRNA.MI Key Statistics
52-Week Range19.38 - 50.5
Current 1MRNA.MI stock price positioned within its 52-week range.
1-Month Range35.39 - 50.5
Current 1MRNA.MI stock price positioned within its 1-month range.
- Market Cap
- 15.973B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.21
- Dividend Yield
- N/A
1MRNA.MI Stock Performance
Today
-11.09%
1 Week
+9.25%
1 Month
+23.59%
3 Months
+75.61%
Longer-term
6 Months +115.84%
1 Year +46.33%
2 Years -51.61%
3 Years N/A
5 Years N/A
10 Years N/A
1MRNA.MI Stock Chart
1MRNA.MI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to 1MRNA.MI. When comparing the yearly performance of all stocks, 1MRNA.MI is one of the better performing stocks in the market, outperforming 93.61% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
1MRNA.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1MRNA.MI. While 1MRNA.MI seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
1MRNA.MI Earnings
On February 13, 2026 1MRNA.MI reported an EPS of -2.11 and a revenue of 678.00M. The company beat EPS expectations (21.71% surprise) and beat revenue expectations (6.17% surprise).
Next Earnings DateMay 1, 2026
Last Earnings DateFeb 13, 2026
PeriodQ4 / 2025
EPS Reported-$2.11
Revenue Reported678M
EPS Surprise 21.71%
Revenue Surprise 6.17%
1MRNA.MI Forecast & Estimates
30 analysts have analysed 1MRNA.MI and the average price target is 38.73 EUR. This implies a price decrease of -3.83% is expected in the next year compared to the current price of 40.275.
For the next year, analysts expect an EPS growth of 1.99% and a revenue growth 10.33% for 1MRNA.MI
Analysts
Analysts56
Price Target38.73 (-3.84%)
EPS Next Y1.99%
Revenue Next Year10.33%
1MRNA.MI Financial Highlights
Over the last trailing twelve months 1MRNA.MI reported a non-GAAP Earnings per Share(EPS) of -6.21. The EPS increased by 21.66% compared to the year before.
Income Statements
Revenue(TTM)1.94B
Net Income(TTM)-2.82B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.87% | ||
| ROE | -32.62% | ||
| Debt/Equity | 0.07 |
Chartmill High Growth Momentum
EPS Q2Q%27.49%
Sales Q2Q%-29.81%
EPS 1Y (TTM)21.66%
Revenue 1Y (TTM)-39.93%
1MRNA.MI Ownership
Ownership
Inst Owners79.19%
Shares396.59M
Float367.57M
Ins Owners2.7%
Short Float %N/A
Short RatioN/A
1MRNA.MI Industry Overview
1MRNA.MI operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.8%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.1
1MRNA.MI Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.81 | 41.543B | ||
| 1AE | ARGENX SE | 28.79 | 41.518B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.443B | ||
| ABVX | ABIVAX SA | N/A | 7.648B | ||
| 2X1 | ABIVAX SA | N/A | 7.64B | ||
| GLPG | GALAPAGOS NV | N/A | 1.591B | ||
| GXE | GALAPAGOS NV | N/A | 1.59B | ||
| NANO | NANOBIOTIX | N/A | 1.39B | ||
| PHARM | PHARMING GROUP NV | 47.29 | 1.011B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.01B | ||
| PHGN | PHARMING GROUP NV | 47.13 | 1.008B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 895.23M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1MRNA.MI
Company Profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
IPO: 2018-12-07
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS US
Employees: 4700
Phone: 16177146500
MODERNA INC / 1MRNA.MI FAQ
Can you describe the business of MODERNA INC?
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
What is the current price of 1MRNA stock?
The current stock price of 1MRNA.MI is 40.275 EUR. The price decreased by -11.09% in the last trading session.
Does 1MRNA stock pay dividends?
1MRNA.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1MRNA stock?
1MRNA.MI has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of 1MRNA stock?
MODERNA INC (1MRNA.MI) has a market capitalization of 15.97B EUR. This makes 1MRNA.MI a Large Cap stock.
What is the ownership structure of MODERNA INC (1MRNA.MI)?
You can find the ownership structure of MODERNA INC (1MRNA.MI) on the Ownership tab.